Janux Therapeutics financials
$16.95+2.23%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $10.0M | $10.6M | $8.1M | $8.6M | $3.6M |
| Gross profit | $10.0M | $10.6M | $8.1M | $8.6M | $3.6M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$157.7M | -$98.8M | -$73.0M | -$67.1M | -$32.9M |
| Net income | -$113.6M | -$69.0M | -$58.3M | -$63.1M | -$32.7M |
| Net margin | −1136.3% | −651.6% | −721.2% | −732.2% | −898.3% |
| Diluted EPS | $-1.83 | $-1.28 | $-1.32 | $-1.52 | $-1.39 |
| EBITDA | -$155.6M | -$96.8M | -$71.0M | -$66.3M | -$32.8M |
| Operating cash flow | -$82.2M | -$43.8M | -$50.6M | -$42.9M | -$17.0M |
| Free cash flow | -$83.3M | -$44.2M | -$52.4M | -$49.4M | -$18.5M |
| Diluted shares | 62.0M | 53.8M | 44.0M | 41.5M | 23.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $52.3M | $430.6M | $19.2M | $51.4M | $35.6M |
| Short-term investments | $914.2M | $594.6M | $324.8M | $275.6M | $339.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.00B | $1.06B | $380.4M | $364.0M | $379.8M |
| Total liabilities | $44.7M | $38.7M | $36.1M | $43.3M | $13.5M |
| Shareholders' equity | $956.8M | $1.02B | $344.3M | $320.7M | $366.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology